Management Team

James Campbell, BSc (Hons), PhD, MBA, GAICD – Chief Executive Officer

Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies.  Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalisation of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M.  Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations.  Dr. Campbell sits on the Advisory Board of Deakin University’s Centre for Innovation in Mental and Physical Health and Clinical Treatment (IMPACT).  Dr. Campbell is a Non-Executive Director of Prescient Therapeutics Limited (ASX:PTX).

Melanie Leydin, B Bus (Acc. Corp. Law) – Company Secretary

Melanie Leydin holds a Bachelor of Business majoring in Accounting and Corporate Law. She is a member of the Institute of Chartered Accountants and is a Registered Company Auditor. She graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of chartered accounting firm, Leydin Freyer. The practice provides outsourced company secretarial and accounting services to public and private companies specialising in the Resources, technology, bioscience and biotechnology sector. Melanie has over 25 years’ experience in the accounting profession and has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.

Deanne Greenwood, BSc (Hons), PhD, MBA, GAICD – Vice President, Business Development & Intellectual Property

Dr. Greenwood joined Patrys in 2008 and has held various roles during that time.  At Patrys, Dr. Greenwood’s efforts are focused on commericalisation of the IgM and Deoxymab assets and management of the extensive intellectual property portfolio.  She has extensive experience related to the R&D drug development, relationship management, contracts and grants.  Dr. Greenwood led the negotiations with Hefei Co-source Biomedical Co. LTD, a Chinese based company which has taken an exclusive license to PAT-SC1.  Prior to joining Patrys, Dr. Greenwood spent 10-years in academia conducting immunology research in the areas of vaccine development and autoimmunity, with the last four years at the Centre for Animal Biotechnology, The University of Melbourne. Dr. Greenwood has a PhD degree in Immunology from the Monash University, Masters of Business Administration (Technology) from La Trobe University and is a graduate of the Australian Institute of Company Directors (GAICD). Dr. Greenwood is a co-author on 11 publications on immunological related topics.

Valentina Dubljevic, MBB, BSc, GAICD – Vice President, Scientific & Clinical Development

Ms. Dubljevic joined Patrys in June 2012 and is responsible for the pre-clinical and clinical development of Patrys’ products. Ms. Dubljevic brings more than 20 years of scientific and commercial experience in the areas of anti- cancer therapies, vaccine development, and diagnostics. Prior to joining Patrys, she worked at the Monash University conducting research on malaria vaccine development; at Cytopia Limited developing small molecule anti-cancer drugs and at Monash Institute of Medical Research (MIMR) developing antibody therapies for cancer. She has extensive experience related to the drug development, management of pre-clinical studies, manufacturing, regulatory and clinical operations, contracts and project management and has co-authored multiple scientific papers and grants.  Ms. Dubljevic holds a Bachelor of Biomedical Science degree from Griffith University, Brisbane, a Masters in Biotechnology and Business degree from RMIT and is a graduate of the Australian Institute of Company Directors (GAICD).